NASDAQ:HRTS Tema Heart & Health ETF (HRTS) Price, Holdings, & News $29.04 +0.20 (+0.69%) As of 02:50 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestTrendsBuy This Stock About Tema Heart & Health ETF (NASDAQ:HRTS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get HRTS alerts:Sign Up Key Stats Today's Range$28.80▼$29.1350-Day Range$26.75▼$29.2852-Week Range$25.32▼$36.03Volume1,914 shsAverage Volume9,309 shsMarket Capitalization$50.53 millionAssets Under Management$50.91 millionDividend Yield1.58%Net Expense Ratio0.75%Aggregate RatingModerate Buy ETF Overview The Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. HRTS was launched on Nov 20, 2023 and is issued by Tema. Read More Tema Heart & Health ETF ExpensesTypeHRTSTheme ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.99%0.57%0.56%0.54%0.53%Other Expenses0.00%0.58%0.56%0.52%0.56%Total Expense0.99%0.74%0.76%0.74%0.73%Fee Waiver-0.24%-0.76%-0.66%-0.50%-0.63%Net Expense0.75%0.60%0.63%0.63%0.60% Receive HRTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tema Heart & Health ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address HRTS ETF News HeadlinesWeight-Loss Drug ETFs Generate Skinnier Returns Than ExpectedJune 11, 2025 | finance.yahoo.comHRTS Tema Obesity & Cardiometabolic ETFApril 10, 2025 | seekingalpha.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.July 14 at 2:00 AM | Brownstone Research (Ad)HRT may help to protect the heartOctober 22, 2024 | dailymail.co.ukInvesting in Real Assets: The Growing Demand and Opportunity with Brompton’s BREA ETFOctober 10, 2024 | theglobeandmail.comOil Prices Spike Amid Middle East TensionsOctober 8, 2024 | theglobeandmail.comSee More Headlines HRTS ETF - Frequently Asked Questions How have HRTS shares performed this year? Tema Heart & Health ETF's stock was trading at $28.87 at the start of the year. Since then, HRTS stock has increased by 0.6% and is now trading at $29.04. Who are Tema Heart & Health ETF's major shareholders? Tema Heart & Health ETF's top institutional shareholders include Oliver Lagore Vanvalin Investment Group (1.73%). How do I buy shares of Tema Heart & Health ETF? Shares of HRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tema Heart & Health ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tema Heart & Health ETF investors own include Scilex (SCLX), Rigetti Computing (RGTI), Pfizer (PFE), BlackBerry (BB), Butterfly Network (BFLY), BioNTech (BNTX) and Fund Details IssuerTema Global Fund NameTema Heart & Health ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:HRTS Inception Date11/20/2023 Fund ManagerDavid Song, Yuri Khodjamirian Previous SymbolNASDAQ:HRTS WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkN/A CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings90 Fund Statistics Assets Under Management$50.91 million Average Daily Volume$0.00 Discount/Premium0.02% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorTema Global Limited CustodianU.S. Bank, N.A. DistributorForeside Fund Services, LLC Transfer AgentU.S. Bancorp Fund Services, LLC TrusteeN/A Lead Market MakerVirtu Financial Options OptionableOptionable Options Volume1 Put Options3 Call Options1 Short Interest800 shs Miscellaneous Outstanding Shares1,740,000Beta0.93 Creation Unit10,000 Creation Fee$500.00 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report Top 10 HRTS HoldingsEli Lilly and Company (NYSE:LLY)Holding Weight: 9.76%Abbott Laboratories (NYSE:ABT)Holding Weight: 4.54%Novo Nordisk A/SHolding Weight: 4.46%Roche (OTCMKTS:RHHBY)Holding Weight: 4.17%AstraZeneca PLCHolding Weight: 4.09%BridgeBio Pharma (NASDAQ:BBIO)Holding Weight: 3.84%UnitedHealth Group (NYSE:UNH)Holding Weight: 3.65%Boston Scientific (NYSE:BSX)Holding Weight: 3.49%Novartis AGHolding Weight: 3.33%Vertex Pharmaceuticals (NASDAQ:VRTX)Holding Weight: 3.24%Full Holdings DetailsHRTS Sector ExposureHRTS Industry Exposure This page (NASDAQ:HRTS) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Heart & Health ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Heart & Health ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.